These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 27998973)

  • 1. Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer.
    M-Rabet M; Cabaud O; Josselin E; Finetti P; Castellano R; Farina A; Agavnian-Couquiaud E; Saviane G; Collette Y; Viens P; Gonçalves A; Ginestier C; Charafe-Jauffret E; Birnbaum D; Olive D; Bertucci F; Lopez M
    Ann Oncol; 2017 Apr; 28(4):769-776. PubMed ID: 27998973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
    Challita-Eid PM; Satpayev D; Yang P; An Z; Morrison K; Shostak Y; Raitano A; Nadell R; Liu W; Lortie DR; Capo L; Verlinsky A; Leavitt M; Malik F; Aviña H; Guevara CI; Dinh N; Karki S; Anand BS; Pereira DS; Joseph IB; Doñate F; Morrison K; Stover DR
    Cancer Res; 2016 May; 76(10):3003-13. PubMed ID: 27013195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming Resistance to Anti-Nectin-4 Antibody-Drug Conjugate.
    Cabaud O; Berger L; Crompot E; Adélaide J; Finetti P; Garnier S; Guille A; Carbuccia N; Farina A; Agavnian E; Chaffanet M; Gonçalves A; Charafe-Jauffret E; Mamessier E; Birnbaum D; Bertucci F; Lopez M
    Mol Cancer Ther; 2022 Jul; 21(7):1227-1235. PubMed ID: 35534238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE.
    Suthe SR; Yao HP; Weng TH; Hu CY; Feng L; Wu ZG; Wang MH
    Mol Cancer Ther; 2018 Dec; 17(12):2654-2664. PubMed ID: 30275241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer Testis Antigen Promotes Triple Negative Breast Cancer Metastasis and is Traceable in the Circulating Extracellular Vesicles.
    Kannan A; Philley JV; Hertweck KL; Ndetan H; Singh KP; Sivakumar S; Wells RB; Vadlamudi RK; Dasgupta S
    Sci Rep; 2019 Aug; 9(1):11632. PubMed ID: 31406142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
    Ring A; Kaur P; Lang JE
    BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
    Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
    J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
    Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
    Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.
    Nelson ER; Li S; Kennedy M; Payne S; Kilibarda K; Groth J; Bowie M; Parilla-Castellar E; de Ridder G; Marcom PK; Lyes M; Peterson BL; Cook M; Pizzo SV; McDonnell DP; Bachelder RE
    Oncotarget; 2016 Dec; 7(51):84030-84042. PubMed ID: 27768598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer.
    Wu Y; Zhu M; Sun B; Chen Y; Huang Y; Gai J; Li G; Li Y; Wan Y; Ma L
    J Nanobiotechnology; 2024 May; 22(1):256. PubMed ID: 38755613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth.
    Cheung A; Chenoweth AM; Johansson A; Laddach R; Guppy N; Trendell J; Esapa B; Mavousian A; Navarro-Llinas B; Haider S; Romero-Clavijo P; Hoffmann RM; Andriollo P; Rahman KM; Jackson P; Tsoka S; Irshad S; Roxanis I; Grigoriadis A; Thurston DE; Lord CJ; Tutt ANJ; Karagiannis SN
    Clin Cancer Res; 2024 Aug; 30(15):3298-3315. PubMed ID: 38772416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers.
    Oshima T; Sato S; Kato J; Ito Y; Watanabe T; Tsuji I; Hori A; Kurokawa T; Kokubo T
    Mol Cancer; 2013 Jun; 12():60. PubMed ID: 23758976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer.
    Leong SR; Liang WC; Wu Y; Crocker L; Cheng E; Sampath D; Ohri R; Raab H; Hass PE; Pham T; Firestein R; Li D; Schutten M; Stagg NJ; Ogasawara A; Koppada N; Roth L; Williams SP; Lee BC; Chalouni C; Peng I; DeVoss J; Tremayne J; Polakis P; Polson AG
    Mol Pharm; 2015 Jun; 12(6):1717-29. PubMed ID: 25853436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
    Bardia A; Mayer IA; Diamond JR; Moroose RL; Isakoff SJ; Starodub AN; Shah NC; O'Shaughnessy J; Kalinsky K; Guarino M; Abramson V; Juric D; Tolaney SM; Berlin J; Messersmith WA; Ocean AJ; Wegener WA; Maliakal P; Sharkey RM; Govindan SV; Goldenberg DM; Vahdat LT
    J Clin Oncol; 2017 Jul; 35(19):2141-2148. PubMed ID: 28291390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nectin-4 Expression Is an Independent Prognostic Biomarker and Associated With Better Survival in Triple-Negative Breast Cancer.
    Zeindler J; Soysal SD; Piscuoglio S; Ng CKY; Mechera R; Isaak A; Weber WP; Muenst S; Kurzeder C
    Front Med (Lausanne); 2019; 6():200. PubMed ID: 31572728
    [No Abstract]   [Full Text] [Related]  

  • 17. Combination of verteporfin-photodynamic therapy with 5-aza-2'-deoxycytidine enhances the anti-tumour immune response in triple negative breast cancer.
    Banerjee SM; Acedo P; El Sheikh S; Harati R; Meecham A; Williams NR; Gerard G; Keshtgar MRS; MacRobert AJ; Hamoudi R
    Front Immunol; 2023; 14():1188087. PubMed ID: 38022682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
    Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGF13 promotes metastasis of triple-negative breast cancer.
    Johnstone CN; Pattison AD; Harrison PF; Powell DR; Lock P; Ernst M; Anderson RL; Beilharz TH
    Int J Cancer; 2020 Jul; 147(1):230-243. PubMed ID: 31957002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.